• New herbicide molecule in early development announced; first new post-emergence mode of action for broad acre weed control in 30 years
• Bayer unveils a third pathway to breakthrough short stature corn through gene editing; two prior concepts advance to Phase 3
• Three generations of herbicide-tolerance traits in soybeans advance phases, representing the industry’s most robust pipeline of weed control biotechnology for soy
• Largest agricultural industry R&D investment of more than 2.3 billion euros annually

• “Decision of EPA corresponds to the long-standing assessments of leading international health authorities”, says Liam Condon, Bayer Board Member
• The Amicus brief of the U.S. Department of Justice in the Hardeman case also support Glyphosate´s safety

CEO Werner Baumann: “We want to help people in the affected regions quickly and effectively”

• Chairman of the Board of Management, Baumann: “As a leading innovation company, we will drive forward a reduction in greenhouse gases throughout our entire value chain”
• Numerous investors factor CDP ratings into investment decisions
• Bayer listed as a leading company by CDP every year since2005

Diegem, 18 décembre 2019 – La semaine qui précède Noël est traditionnellement la plus chaleureuse, c’est le cas chez Bayer aussi. Tout comme l’année dernière, les équipes des sites belges de Bayer ont organisé des actions pour la ‘Warmste Week’ (le penchant néerlandophone de Viva for Life). Au total, les employés ont récolté 19.000 euros au profit de la Ligue Cardiologique Belge. C’est l’équipe Clinical Operations qui a organisé l’action la plus lucrative et qui ira donc remettre le chèque à Courtrai.

• Objectif 2030 : être neutre en carbone dans toutes nos activités
• Des objectifs ambitieux pour 2030 concernant l’accès à la santé et à la nutrition dans les pays à revenu faible et intermédiaire et dans les communautés mal desservies
• Des objectifs mesurables pour le développement durable à intégrer dans la rémunération des dirigeants

• Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros
• EBITDA before special items advances by 7.5 percent to 2.291 billion euros
• Crop Science reports higher sales and substantial earnings growth
• Pharmaceuticals increases sales – earnings decline due to one-time income in prior year
• Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings
• Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year
• Core earnings per share up by 6.4 percent to 1.16 euros
• Group outlook confirmed and aligned to continuing operations

• Agriculture is part of the solution for climate change
• Investing more than 25 billion euros in Crop Science R&D over the next 10 years
• Leading Digital Farming platform FieldView on 90 million paid acres this year